Atlas Trials

Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma

Clinical trial NCT04002622 · TERMINATED

Trial details

NCT number
NCT04002622
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
Start date
2019-08-06
Primary completion
2021-01-21
Enrollment
1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.